Free Trial
→ Dr. Ron Paul: “It’s time to prepare” (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$2.81
+7.2%		$2.65
$1.35
▼
$4.49
$225.42M0.951.15 million shs1,533 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$11.15
+2.9%		$11.27
$9.69
▼
$22.55
$221.40M1.13297,286 shs101 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7.29
$7.16
$3.53
▼
$7.55
$53.86M0.4125,152 shs616,000 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.66
+1.7%		$2.65
$1.65
▼
$3.19
$214.16M-0.09890,240 shs5,332 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
0.00%+8.71%+5.22%-23.84%-39.91%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
+0.65%-5.25%-4.67%+8.41%-28.84%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.00%0.00%0.00%0.00%+18.92%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
+1.95%+3.16%-3.69%+6.97%+9.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$2.81
+7.2%		$2.65
$1.35
▼
$4.49
$225.42M0.951.15 million shs1,533 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$11.15
+2.9%		$11.27
$9.69
▼
$22.55
$221.40M1.13297,286 shs101 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7.29
$7.16
$3.53
▼
$7.55
$53.86M0.4125,152 shs616,000 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.66
+1.7%		$2.65
$1.65
▼
$3.19
$214.16M-0.09890,240 shs5,332 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
0.00%+8.71%+5.22%-23.84%-39.91%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
+0.65%-5.25%-4.67%+8.41%-28.84%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.00%0.00%0.00%0.00%+18.92%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
+1.95%+3.16%-3.69%+6.97%+9.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
2.33
Hold$10.00256.13% Upside
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.33
Hold$20.5083.91% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
1.00
SellN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$12.00351.98% Upside

Current Analyst Ratings Breakdown

Latest KZR, KROS, ELDN, and PLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/9/2026
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$12.00
8/27/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
8/12/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
8/4/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$20.00 ➝ $18.00
8/4/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$20.00
8/4/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$30.00 ➝ $23.00
(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$1.35 per shareN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$244.06M0.91$4.68 per share2.38$15.51 per share0.72
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/A$9.57 per shareN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$80.62M2.65$0.15 per share17.80$0.47 per share5.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$45.62M-$0.91N/AN/AN/AN/A-149.63%-50.84%11/13/2026 (Estimated)
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$87.01M-$3.70N/AN/AN/A-256.60%-21.40%-19.79%11/4/2026 (Estimated)
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$56.03M-$6.17N/AN/AN/AN/A-55.42%-47.87%N/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.23N/A8.56N/A-21.03%-30.89%-11.74%N/A

Latest KZR, KROS, ELDN, and PLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.20N/AN/AN/AN/AN/A
11/4/2026Q3 2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$0.96N/AN/AN/A$14.76 millionN/A
8/13/2026Q2 2026
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.1580-$0.27-$0.1120-$0.27N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
7.90
7.90
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
21.96
21.96
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/A
11.52
11.52
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27

Institutional Ownership

CompanyInstitutional Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%

Insider Ownership

CompanyInsider Ownership
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
9.60%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
12.60%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
10.40%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
3381.26 million73.46 millionOptionable
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
9219.83 million17.33 millionOptionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.39 million6.70 millionNot Optionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
22680.57 million69.00 millionOptionable

Recent News About These Companies

Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026
November 3 at 7:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-third-quarter-2026-financial-results-and-business-update-on-november-10-2026-302927769.html
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947177-protalix-biotherapeutics-inc-plx-presents-at-morgan-stanley-24th-annual-global-healthcare
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
September 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-participate-in-upcoming-september-2026-investor-conferences-302872165.html
Protalix (PLX) Q2 2026 Earnings Call Transcript
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/protalix-plx-q2-2026-earnings-142833654.html
Protalix BioTherapeutics (NYSEAMERICAN:PLX) Advances Plant-Cell Protein Programs
August 16, 2026  |  kalkinemedia.comK
PLX: Elfabrio estimates up
August 13, 2026  |  msn.comhttps://www.msn.com/en-us/health/medical/plx-elfabrio-estimates-up/ar-AA2a3iaX
Protalix signals Elfabrio path to 15% to 20% Fabry market share by 2031, backed by Europe every-4-weeks approval
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4631765-protalix-signals-elfabrio-path-to-15-percent-to-20-percent-fabry-market-share-by-2031-backed
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
August 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935453-protalix-biotherapeutics-inc-plx-q2-2026-earnings-call-transcript
Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
August 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69289916-protalix-biotherapeutics-inc-protalix-biotherapeutics-reports-second-quarter-2026-financial-and-business-results-008.htm
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
August 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-second-quarter-2026-financial-and-business-results-302849539.html
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
August 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-second-quarter-2026-financial-results-and-business-update-on-august-12-2026-302843662.html
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary
May 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/protalix-biotherapeutics-inc-q1-2026-003442858.html
PLX: Chiesi Milestone Received
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/plx-chiesi-milestone-received-165500361.html
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript
May 14, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/protalix-biotherapeutics-inc-amexplx-q1-2026-earnings-call-transcript-1762043/
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
May 14, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/transcript-protalix-biotherapeutics-q1-2026-121950605.html
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
May 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/protalix-biotherapeutics-inc-plx-q1-230245793.html
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
May 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4903948-protalix-biotherapeutics-inc-plx-q1-2026-earnings-call-transcript
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
May 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-reports-first-quarter-2026-financial-and-business-results-302770790.html
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
May 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-first-quarter-2026-financial-results-and-business-update-on-may-13-2026-302763976.html
Protalix: Elfabrio Struggles Against Oral Competition
April 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4891005-protalix-elfabrio-struggles-against-oral-competition

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$2.81 +0.19 (+7.18%)
As of 09:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Keros Therapeutics stock logo

Keros Therapeutics NASDAQ:KROS

$11.15 +0.32 (+2.93%)
As of 09:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$2.66 +0.05 (+1.72%)
As of 09:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas